Co-Diagnostics, Inc.

As of June 30, 2026, Co-Diagnostics, Inc. carries a market capitalization of 15.54M, placing it among publicly traded companies globally. Its enterprise value stands at 13.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Co-Diagnostics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Co-Diagnostics, Inc. has 4.88M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 10.95, and the price-to-book ratio stands at 1.22.

These figures are as of June 30, 2026. The EV/Sales ratio of 18.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.69M versus a market cap of 15.54M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Co-Diagnostics, Inc. maintains a current ratio of 1.81, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Co-Diagnostics, Inc. posted a negative return on equity (ROE) of -174.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -149.25, reflecting losses generated across the asset base. The company generates approximately 6,049.37 in revenue per employee across its workforce of 119.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.42 indicates how many times Co-Diagnostics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Co-Diagnostics, Inc. recorded an income tax benefit of -1.62M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -48.68M and -47.06M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Co-Diagnostics, Inc.'s stock has declined approximately 94.15% over the past 52 weeks. The 50-day moving average sits at 1.10, while the 200-day moving average is 2.45.

Over the twelve months ended June 30, 2026, Co-Diagnostics, Inc. generated 721,387.00 in revenue and converted that into -47.06M in net income, yielding earnings per share of -18.97. EBITDA reached -47.97M, while operating income came in at -30.08M.

As of June 30, 2026, Co-Diagnostics, Inc. holds 3.65M in cash and equivalents against 1.80M in total debt, resulting in a net debt position of -3.65M. Total book value stands at 12.71M, with working capital of 2.33M providing operational flexibility.

Co-Diagnostics, Inc. produced -27.10M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -367,372.00 in capital expenditures, free cash flow totaled -27.47M - equivalent to -11.08 per share.

Over the twelve months ended June 30, 2026, Co-Diagnostics, Inc. posted a gross margin of 43.48, reflecting its pricing power and cost economics. The operating margin of -4,170.14 and net profit margin of -6,523.04 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -347.73: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -116.49, meaning Co-Diagnostics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Co-Diagnostics, Inc.'s most recent stock split took place on January 6, 2026 with a 30:1 split ratio.

As of June 30, 2026, Co-Diagnostics, Inc. has an Altman Z-Score of -22.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.